BIOFARMACEUTICK\u00c9 ANAL\u00ddZY<\/h3><\/span><\/div><\/div><\/div>Nab\u00edz\u00edme komplexn\u00ed slu\u017eby v oblasti anal\u00fdzy biologick\u00fdch l\u00e9\u010div, v\u010detn\u011b charakterizace protein\u016f a peptid\u016f, cell-based assays<\/strong>, bioanalytick\u00e9 validace metod a p\u0159enos\u016f metod. Na\u0161e podpora preklinick\u00fdch a klinick\u00fdch studi\u00ed zahrnuje v\u00fdpo\u010dty PK\/PD, testov\u00e1n\u00ed imunogenity a testov\u00e1n\u00ed potency pomoc\u00ed cell-based assays. Prov\u00e1d\u00edme testov\u00e1n\u00ed \u0161irok\u00e9 \u0161k\u00e1ly biologick\u00fdch l\u00e9\u010div. Jako GLP-certifikovan\u00e1 a GCP-kompatibiln\u00ed CRO poskytujeme p\u0159enos metod, validace a v\u00fdvoj metod.<\/p>\n<\/div><\/div><\/div><\/div><\/div>- Anal\u00fdza velk\u00fdch molekul<\/div><\/a><\/li>
- Charakterizace a \u010distota protein\u016f<\/div><\/a><\/li>
- Imunochemick\u00e9 vlastnosti<\/div><\/a><\/li>
- Heterogenita<\/div><\/a><\/li>
- Proteomick\u00e9 slu\u017eby<\/div><\/a><\/li>
- Kvantifikace v biologick\u00e9 materi\u00e1lu<\/div><\/a><\/li>
- Vazba na plazmatick\u00e9 b\u00edlkoviny<\/div><\/a><\/li>
- Tk\u00e1\u0148ov\u00e1 laborato\u0159<\/div><\/a><\/li><\/ul><\/div>
- Anal\u00fdza velk\u00fdch molekul<\/div><\/a><\/li><\/ul><\/div>\n
Anal\u00fdza velk\u00fdch molekul<\/h2>\n
Na\u0161e odd\u011blen\u00ed biopharmaceutick\u00e9 anal\u00fdzy nab\u00edz\u00ed komplexn\u00ed slu\u017eby v oblasti anal\u00fdzy biologick\u00fdch l\u00e9\u010div, v\u010detn\u011b:<\/p>\n
\n- Charakterizace protein\u016f a peptid\u016f<\/strong> \u2013 Podrobn\u00e1 anal\u00fdza a profilov\u00e1n\u00ed.<\/li>\n
- Bioanalytick\u00e1 validace metod<\/strong> \u2013 Zaji\u0161t\u011bn\u00ed validace metod v GxP prost\u0159ed\u00ed.<\/li>\n
- P\u0159enosy metod a QC<\/strong> \u2013 Bezprobl\u00e9mov\u00e9 p\u0159enosy metod a p\u0159\u00edsn\u00e1 kontrola kvality.<\/li>\n
- V\u00fdstupn\u00ed testov\u00e1n\u00ed<\/strong> \u2013 Vybran\u00e9 testov\u00e1n\u00ed v souladu s doporu\u010den\u00edmi ICH-Q6B.<\/li>\n
- Podpora preklinick\u00fdch a klinick\u00fdch studi\u00ed<\/strong> \u2013 Stanoven\u00ed vysokomolekul\u00e1rn\u00edch l\u00e9\u010div v biologick\u00fdch matric\u00edch, testov\u00e1n\u00ed imunogenity (celkov\u00e9 ADA), statistick\u00e9 vyhodnocen\u00ed farmakokinetick\u00fdch (PK) parametr\u016f a hodnocen\u00ed bioekvivalence.<\/li>\n
- Cell-based assays<\/strong> \u2013 Funk\u010dn\u00ed testy hodnot\u00edc\u00ed aktivitu, potenci a imunogenitu l\u00e9\u010div. Pou\u017e\u00edvaj\u00ed se pro testov\u00e1n\u00ed p\u0159i uvol\u0148ov\u00e1n\u00ed \u0161ar\u017e\u00ed, klinick\u00e9 studie a v\u00fdvoj biologick\u00fdch l\u00e9\u010div. Pom\u00e1haj\u00ed definovat terapeutick\u00e9 koncentrace, hodnotit imunogenn\u00ed odpov\u011bdi a zaji\u0161\u0165uj\u00ed bezpe\u010dnost l\u00e9\u010div.<\/li>\n<\/ul>\n
V Quinta \u2013 Analytica klademe d\u016fraz na centralizovan\u00e9 \u0159\u00edzen\u00ed projekt\u016f. Ka\u017ed\u00fd partner m\u00e1 p\u0159id\u011blen\u00e9ho projektov\u00e9ho mana\u017eera se zku\u0161enostmi s komplexn\u00edmi projekty. Tito mana\u017ee\u0159i jsou podporov\u00e1ni na\u0161imi vedouc\u00edmi odd\u011blen\u00ed, kte\u0159\u00ed maj\u00ed bohat\u00e9 praktick\u00e9 zku\u0161enosti a siln\u00e9 teoretick\u00e9 znalosti.<\/p>\n
Na\u0161e za\u0159\u00edzen\u00ed je vybaveno \u0161irokou \u0161k\u00e1lou analytick\u00fdch p\u0159\u00edstroj\u016f pro anal\u00fdzu biologick\u00fdch l\u00e9\u010div, jako jsou ELISA, ECLA, SPR, NGS, PCR, SoloVPE, Maurice, bun\u011b\u010dn\u00e9 eseje<\/a> a UHPLC-MS\/MS. To n\u00e1m umo\u017e\u0148uje prov\u00e1d\u011bt komplexn\u00ed testov\u00e1n\u00ed pro v\u00fdchoz\u00ed materi\u00e1ly, l\u00e9\u010div\u00e9 l\u00e1tky, meziprodukty a fin\u00e1ln\u00ed produkty biologick\u00fdch l\u00e9\u010div. Nab\u00edz\u00edme bioanalytick\u00e9 slu\u017eby pro \u0161irokou \u0161k\u00e1lu biologick\u00fdch l\u00e9\u010div, v\u010detn\u011b inovativn\u00edch protein\u016f, biosimil\u00e1rn\u00edch p\u0159\u00edpravk\u016f, konjug\u00e1t\u016f protil\u00e1tek (ADC), terapeutick\u00fdch peptid\u016f, enzym\u016f, biomarker\u016f, monoklon\u00e1ln\u00edch protil\u00e1tek, hormon\u016f a oligonukleotid\u016f.<\/p>\nJako GLP-certifikovan\u00e1 a GCP-kompatibiln\u00ed organizace pro klinick\u00fd v\u00fdzkum (CRO) excelujeme v p\u0159enosu metod, validac\u00edch metod a v\u00fdvoji bioanalytick\u00fdch metod. N\u00e1\u0161 t\u00fdm je p\u0159ipraven podpo\u0159it PK\/PD bioanalytiku, v\u010detn\u011b v\u00fdpo\u010dt\u016f a imunogenity, jako je hodnocen\u00ed vazby protil\u00e1tek proti l\u00e9k\u016fm (ADA).<\/p>\n
Schopnosti spole\u010dnosti Quinta \u2013 Analytica sahaj\u00ed daleko za r\u00e1mec anal\u00fdzy velk\u00fdch molekul. Zvl\u00e1d\u00e1me komplexn\u00ed projekty v r\u016fzn\u00fdch oblastech farmaceutick\u00e9ho pr\u016fmyslu, v\u010detn\u011b anal\u00fdzy mal\u00fdch molekul<\/a>, analytick\u00e9ho R&D<\/a>, bioanalytick\u00e9ho testov\u00e1n\u00ed<\/a> a klinick\u00fdch studi\u00ed<\/a>. Na\u0161e komplexn\u00ed slu\u017eby zaji\u0161\u0165uj\u00ed, \u017ee spln\u00edme r\u016fznorod\u00e9 pot\u0159eby na\u0161ich klient\u016f a poskytujeme vysoce kvalitn\u00ed \u0159e\u0161en\u00ed pro ka\u017edou f\u00e1zi v\u00fdvoje l\u00e9\u010div.<\/p>\n<\/div>- Charakterizace a \u010distota protein\u016f<\/div><\/a><\/li><\/ul><\/div>\n
Charakterizace a \u010distota protein\u016f<\/h2>\n
Na z\u00e1klad\u011b ICH-Q6B regul\u00ed je doporu\u010deno proteiny a peptidy charakterizovat podle jejich vzhledu, molekulov\u00e9 hmotnosti, izoelektrick\u00e9ho bodu, pH v roztoku, obsahu aminokyselin, prim\u00e1rn\u00ed struktury a polohy disulfidov\u00fdch m\u016fstk\u016f.Anal\u00fdza \u010distoty je velice d\u016fle\u017eitou sou\u010d\u00e1st\u00ed komplexn\u00ed charakterizace aktivn\u00edch slo\u017eek na proteinov\u00e9 nebo peptidov\u00e9 b\u00e1zi. Nadlimitn\u00ed p\u0159\u00edtomnost proteinov\u00fdch agreg\u00e1t\u016f, zbytkov\u00fdch nukleov\u00fdch kyselin nebo bakteri\u00e1ln\u00edch endotoxin\u016f toti\u017e m\u016f\u017ee v lidsk\u00e9m organismu vyvolat ne\u017e\u00e1douc\u00ed a potenci\u00e1ln\u011b \u017eivotu nebezpe\u010dnou imunitn\u00ed reakci.<\/div>
- Imunochemick\u00e9 vlastnosti<\/div><\/a><\/li><\/ul><\/div>\n
Imunochemick\u00e9 vlastnosti<\/h2>\n
Zhodnocen\u00ed imunochemick\u00fdch vlastnost\u00ed dan\u00e9ho proteinov\u00e9ho l\u00e9\u010diva se st\u00e1v\u00e1 nutnost\u00ed, zvl\u00e1\u0161t\u011b pokud toto l\u00e9\u010divo spad\u00e1 do kategorie protil\u00e1tek. V takov\u00fdch p\u0159\u00edpadech je vy\u017eadov\u00e1na charakterizace afinity l\u00e9\u010diva ke specifick\u00fdm antigen\u016fm nebo jejich dob\u0159e definovan\u00fdm \u010d\u00e1stem. Dal\u0161\u00ed ned\u00edlnou sou\u010d\u00e1st\u00ed t\u00e9to charakterizace je testov\u00e1n\u00ed imunitn\u00ed odezvy a m\u00edry tvorby ADA (anti-drug antibodies).<\/div>
- Heterogenita<\/div><\/a><\/li><\/ul><\/div>\n
Heterogenita<\/h2>\n
Aminokyseliny mohou b\u00fdt pom\u011brn\u011b snadno chemicky modifikov\u00e1ny, d\u00edky tomu pak proteiny \u010dasto obsahuj\u00ed \u0159adu post-transla\u010dn\u00edch modifikac\u00ed (PTMs). Tyto modifikace obvykle nelze predikovat ze sekvence k\u00f3duj\u00edc\u00edho genu, ale jeliko\u017e maj\u00ed z\u00e1sadn\u00ed vliv na celkovou funkci proteinu, jejich pops\u00e1n\u00ed je ned\u00edlnou sou\u010d\u00e1st\u00ed komplexn\u00ed charakterizace biologick\u00fdch l\u00e9\u010div.<\/div>
- Proteomick\u00e9 slu\u017eby<\/div><\/a><\/li><\/ul><\/div>\n
Proteomick\u00e9 slu\u017eby<\/h2>\n
Nab\u00edz\u00edme identifikaci protein\u016f a peptid\u016f ve sm\u011bs\u00edch (nap\u0159. rostlinn\u00e9 a \u017eivo\u010di\u0161n\u00e9 extrakty, v\u00edceslo\u017ekov\u00e9 biofarmaceutick\u00e9 prepar\u00e1ty) pomoc\u00ed 2D LC-MS\/MS.<\/div>
- Kvantifikace v biologick\u00e9 materi\u00e1lu<\/div><\/a><\/li><\/ul><\/div>\n
Kvantifikace v biologick\u00e9 materi\u00e1lu<\/h2>\n
Krom\u011b z\u00e1kladn\u00ed charakterizace peptidov\u00fdch a proteinov\u00fdch l\u00e9\u010div prov\u00e1d\u00edme i stanoven\u00ed t\u011bchto l\u00e1tek v biologick\u00e9m materi\u00e1lu metodami LC-MS a ELISA v re\u017eimech spr\u00e1vn\u00e9 laboratorn\u00ed a klinick\u00e9 praxe. Na\u0161e laborato\u0159 je vybavena syst\u00e9my UPLC, LC-FTMS, ELISA (UV-VIS, fluorescence, elektrochemiluminiscence), kapil\u00e1rn\u00ed elektrofor\u00e9za, gelov\u00e1 elektrofor\u00e9za, isoelektrick\u00e9 fokusov\u00e1n\u00ed a syst\u00e9mem pro automatickou anal\u00fdzu aminokyselin.<\/div>
- Vazba na plazmatick\u00e9 b\u00edlkoviny<\/div><\/a><\/li><\/ul><\/div>\n
Vazba na plazmatick\u00e9 b\u00edlkoviny<\/h2>\n
Pro v\u00fdvoj l\u00e9\u010div je z\u00e1sadn\u00ed stanovit a zn\u00e1t stupe\u0148 vazby mal\u00fdch molekul na b\u00edlkoviny, proto\u017ee to p\u0159\u00edmo ovliv\u0148uje rychlost vylu\u010dov\u00e1n\u00ed p\u0159\u00edpravku, v n\u011bkter\u00fdch p\u0159\u00edpadech to m\u016f\u017ee b\u00fdt a\u017e 95 – 99%, a naopak to ur\u010duje celkovou \u00fa\u010dinnost l\u00e9\u010div.<\/p>\n
QUINTA-ANALYTICA pou\u017e\u00edv\u00e1 ke stanoven\u00ed t\u00e9to vazby kombinaci ekvilibra\u010dn\u00ed dial\u00fdzy a LC-MS\/MS.<\/p>\n
Za\u0159\u00edzen\u00ed m\u00e1 dv\u011b kom\u016frky spojen\u00e9 membr\u00e1nou s p\u00f3ry, kter\u00e9 propou\u0161t\u00ed pouze molekuly do ur\u010dit\u00e9 velikosti. Do jedn\u00e9 kom\u016frky je pipetov\u00e1n vzorek plasmy nebo proteinu (nej\u010dast\u011bji albumin) s analytem, do druh\u00e9 kom\u016frky pak pouze pufr. Po ust\u00e1len\u00ed rovnov\u00e1hy je d\u00edky voln\u00e9mu pohybu mal\u00e9 molekuly p\u0159es membr\u00e1nu jej\u00ed koncentrace v obou komor\u00e1ch stejn\u00e1 a odpov\u00edd\u00e1 mno\u017estv\u00ed l\u00e1tky na protein nenav\u00e1zan\u00e9.<\/div>
Nab\u00edz\u00edme komplexn\u00ed slu\u017eby v oblasti anal\u00fdzy biologick\u00fdch l\u00e9\u010div, v\u010detn\u011b charakterizace protein\u016f a peptid\u016f, cell-based assays<\/strong>, bioanalytick\u00e9 validace metod a p\u0159enos\u016f metod. Na\u0161e podpora preklinick\u00fdch a klinick\u00fdch studi\u00ed zahrnuje v\u00fdpo\u010dty PK\/PD, testov\u00e1n\u00ed imunogenity a testov\u00e1n\u00ed potency pomoc\u00ed cell-based assays. Prov\u00e1d\u00edme testov\u00e1n\u00ed \u0161irok\u00e9 \u0161k\u00e1ly biologick\u00fdch l\u00e9\u010div. Jako GLP-certifikovan\u00e1 a GCP-kompatibiln\u00ed CRO poskytujeme p\u0159enos metod, validace a v\u00fdvoj metod.<\/p>\n<\/div><\/div><\/div><\/div><\/div> Na\u0161e odd\u011blen\u00ed biopharmaceutick\u00e9 anal\u00fdzy nab\u00edz\u00ed komplexn\u00ed slu\u017eby v oblasti anal\u00fdzy biologick\u00fdch l\u00e9\u010div, v\u010detn\u011b:<\/p>\n V Quinta \u2013 Analytica klademe d\u016fraz na centralizovan\u00e9 \u0159\u00edzen\u00ed projekt\u016f. Ka\u017ed\u00fd partner m\u00e1 p\u0159id\u011blen\u00e9ho projektov\u00e9ho mana\u017eera se zku\u0161enostmi s komplexn\u00edmi projekty. Tito mana\u017ee\u0159i jsou podporov\u00e1ni na\u0161imi vedouc\u00edmi odd\u011blen\u00ed, kte\u0159\u00ed maj\u00ed bohat\u00e9 praktick\u00e9 zku\u0161enosti a siln\u00e9 teoretick\u00e9 znalosti.<\/p>\n Na\u0161e za\u0159\u00edzen\u00ed je vybaveno \u0161irokou \u0161k\u00e1lou analytick\u00fdch p\u0159\u00edstroj\u016f pro anal\u00fdzu biologick\u00fdch l\u00e9\u010div, jako jsou ELISA, ECLA, SPR, NGS, PCR, SoloVPE, Maurice, bun\u011b\u010dn\u00e9 eseje<\/a> a UHPLC-MS\/MS. To n\u00e1m umo\u017e\u0148uje prov\u00e1d\u011bt komplexn\u00ed testov\u00e1n\u00ed pro v\u00fdchoz\u00ed materi\u00e1ly, l\u00e9\u010div\u00e9 l\u00e1tky, meziprodukty a fin\u00e1ln\u00ed produkty biologick\u00fdch l\u00e9\u010div. Nab\u00edz\u00edme bioanalytick\u00e9 slu\u017eby pro \u0161irokou \u0161k\u00e1lu biologick\u00fdch l\u00e9\u010div, v\u010detn\u011b inovativn\u00edch protein\u016f, biosimil\u00e1rn\u00edch p\u0159\u00edpravk\u016f, konjug\u00e1t\u016f protil\u00e1tek (ADC), terapeutick\u00fdch peptid\u016f, enzym\u016f, biomarker\u016f, monoklon\u00e1ln\u00edch protil\u00e1tek, hormon\u016f a oligonukleotid\u016f.<\/p>\n Jako GLP-certifikovan\u00e1 a GCP-kompatibiln\u00ed organizace pro klinick\u00fd v\u00fdzkum (CRO) excelujeme v p\u0159enosu metod, validac\u00edch metod a v\u00fdvoji bioanalytick\u00fdch metod. N\u00e1\u0161 t\u00fdm je p\u0159ipraven podpo\u0159it PK\/PD bioanalytiku, v\u010detn\u011b v\u00fdpo\u010dt\u016f a imunogenity, jako je hodnocen\u00ed vazby protil\u00e1tek proti l\u00e9k\u016fm (ADA).<\/p>\n Schopnosti spole\u010dnosti Quinta \u2013 Analytica sahaj\u00ed daleko za r\u00e1mec anal\u00fdzy velk\u00fdch molekul. Zvl\u00e1d\u00e1me komplexn\u00ed projekty v r\u016fzn\u00fdch oblastech farmaceutick\u00e9ho pr\u016fmyslu, v\u010detn\u011b anal\u00fdzy mal\u00fdch molekul<\/a>, analytick\u00e9ho R&D<\/a>, bioanalytick\u00e9ho testov\u00e1n\u00ed<\/a> a klinick\u00fdch studi\u00ed<\/a>. Na\u0161e komplexn\u00ed slu\u017eby zaji\u0161\u0165uj\u00ed, \u017ee spln\u00edme r\u016fznorod\u00e9 pot\u0159eby na\u0161ich klient\u016f a poskytujeme vysoce kvalitn\u00ed \u0159e\u0161en\u00ed pro ka\u017edou f\u00e1zi v\u00fdvoje l\u00e9\u010div.<\/p>\n<\/div> Na z\u00e1klad\u011b ICH-Q6B regul\u00ed je doporu\u010deno proteiny a peptidy charakterizovat podle jejich vzhledu, molekulov\u00e9 hmotnosti, izoelektrick\u00e9ho bodu, pH v roztoku, obsahu aminokyselin, prim\u00e1rn\u00ed struktury a polohy disulfidov\u00fdch m\u016fstk\u016f.Anal\u00fdza \u010distoty je velice d\u016fle\u017eitou sou\u010d\u00e1st\u00ed komplexn\u00ed charakterizace aktivn\u00edch slo\u017eek na proteinov\u00e9 nebo peptidov\u00e9 b\u00e1zi. Nadlimitn\u00ed p\u0159\u00edtomnost proteinov\u00fdch agreg\u00e1t\u016f, zbytkov\u00fdch nukleov\u00fdch kyselin nebo bakteri\u00e1ln\u00edch endotoxin\u016f toti\u017e m\u016f\u017ee v lidsk\u00e9m organismu vyvolat ne\u017e\u00e1douc\u00ed a potenci\u00e1ln\u011b \u017eivotu nebezpe\u010dnou imunitn\u00ed reakci.<\/div> Zhodnocen\u00ed imunochemick\u00fdch vlastnost\u00ed dan\u00e9ho proteinov\u00e9ho l\u00e9\u010diva se st\u00e1v\u00e1 nutnost\u00ed, zvl\u00e1\u0161t\u011b pokud toto l\u00e9\u010divo spad\u00e1 do kategorie protil\u00e1tek. V takov\u00fdch p\u0159\u00edpadech je vy\u017eadov\u00e1na charakterizace afinity l\u00e9\u010diva ke specifick\u00fdm antigen\u016fm nebo jejich dob\u0159e definovan\u00fdm \u010d\u00e1stem. Dal\u0161\u00ed ned\u00edlnou sou\u010d\u00e1st\u00ed t\u00e9to charakterizace je testov\u00e1n\u00ed imunitn\u00ed odezvy a m\u00edry tvorby ADA (anti-drug antibodies).<\/div> Aminokyseliny mohou b\u00fdt pom\u011brn\u011b snadno chemicky modifikov\u00e1ny, d\u00edky tomu pak proteiny \u010dasto obsahuj\u00ed \u0159adu post-transla\u010dn\u00edch modifikac\u00ed (PTMs). Tyto modifikace obvykle nelze predikovat ze sekvence k\u00f3duj\u00edc\u00edho genu, ale jeliko\u017e maj\u00ed z\u00e1sadn\u00ed vliv na celkovou funkci proteinu, jejich pops\u00e1n\u00ed je ned\u00edlnou sou\u010d\u00e1st\u00ed komplexn\u00ed charakterizace biologick\u00fdch l\u00e9\u010div.<\/div> Nab\u00edz\u00edme identifikaci protein\u016f a peptid\u016f ve sm\u011bs\u00edch (nap\u0159. rostlinn\u00e9 a \u017eivo\u010di\u0161n\u00e9 extrakty, v\u00edceslo\u017ekov\u00e9 biofarmaceutick\u00e9 prepar\u00e1ty) pomoc\u00ed 2D LC-MS\/MS.<\/div> Krom\u011b z\u00e1kladn\u00ed charakterizace peptidov\u00fdch a proteinov\u00fdch l\u00e9\u010div prov\u00e1d\u00edme i stanoven\u00ed t\u011bchto l\u00e1tek v biologick\u00e9m materi\u00e1lu metodami LC-MS a ELISA v re\u017eimech spr\u00e1vn\u00e9 laboratorn\u00ed a klinick\u00e9 praxe. Na\u0161e laborato\u0159 je vybavena syst\u00e9my UPLC, LC-FTMS, ELISA (UV-VIS, fluorescence, elektrochemiluminiscence), kapil\u00e1rn\u00ed elektrofor\u00e9za, gelov\u00e1 elektrofor\u00e9za, isoelektrick\u00e9 fokusov\u00e1n\u00ed a syst\u00e9mem pro automatickou anal\u00fdzu aminokyselin.<\/div> Pro v\u00fdvoj l\u00e9\u010div je z\u00e1sadn\u00ed stanovit a zn\u00e1t stupe\u0148 vazby mal\u00fdch molekul na b\u00edlkoviny, proto\u017ee to p\u0159\u00edmo ovliv\u0148uje rychlost vylu\u010dov\u00e1n\u00ed p\u0159\u00edpravku, v n\u011bkter\u00fdch p\u0159\u00edpadech to m\u016f\u017ee b\u00fdt a\u017e 95 – 99%, a naopak to ur\u010duje celkovou \u00fa\u010dinnost l\u00e9\u010div.<\/p>\n QUINTA-ANALYTICA pou\u017e\u00edv\u00e1 ke stanoven\u00ed t\u00e9to vazby kombinaci ekvilibra\u010dn\u00ed dial\u00fdzy a LC-MS\/MS.<\/p>\n Za\u0159\u00edzen\u00ed m\u00e1 dv\u011b kom\u016frky spojen\u00e9 membr\u00e1nou s p\u00f3ry, kter\u00e9 propou\u0161t\u00ed pouze molekuly do ur\u010dit\u00e9 velikosti. Do jedn\u00e9 kom\u016frky je pipetov\u00e1n vzorek plasmy nebo proteinu (nej\u010dast\u011bji albumin) s analytem, do druh\u00e9 kom\u016frky pak pouze pufr. Po ust\u00e1len\u00ed rovnov\u00e1hy je d\u00edky voln\u00e9mu pohybu mal\u00e9 molekuly p\u0159es membr\u00e1nu jej\u00ed koncentrace v obou komor\u00e1ch stejn\u00e1 a odpov\u00edd\u00e1 mno\u017estv\u00ed l\u00e1tky na protein nenav\u00e1zan\u00e9.<\/div>Anal\u00fdza velk\u00fdch molekul<\/h2>\n
\n
Charakterizace a \u010distota protein\u016f<\/h2>\n
Imunochemick\u00e9 vlastnosti<\/h2>\n
Heterogenita<\/h2>\n
Proteomick\u00e9 slu\u017eby<\/h2>\n
Kvantifikace v biologick\u00e9 materi\u00e1lu<\/h2>\n
Vazba na plazmatick\u00e9 b\u00edlkoviny<\/h2>\n
![](\"https:\/\/www.quinta.cz\/wp-content\/uploads\/2023\/04\/weapons-2.png\" "\\"weapons-2\\"")
<\/span><\/div>![](\"https:\/\/www.quinta.cz\/wp-content\/uploads\/2023\/04\/medical.png\" "\\"medical\\"")
<\/span><\/div>![](\"https:\/\/www.quinta.cz\/wp-content\/uploads\/2023\/04\/medical-5.png\" "\\"medical-5\\"")
<\/span><\/div>![](\"https:\/\/www.quinta.cz\/wp-content\/uploads\/2023\/04\/avatar.png\" "\\"avatar\\""){kind=avatar}
<\/span><\/div>![](\"https:\/\/www.quinta.cz\/wp-content\/uploads\/2023\/04\/map-point.png\" "\\"map-point\\"")
<\/span><\/div>